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Mode of Action of Heparin and Related Drugs
H. COENRAAD HEMKER, Ph.D.,  and SUZETTE BEGUIN, Ph.D.
There are three main classes of antithrombotic
drugs: Platelet inhibitors, oral anticoagulants, and drugs
such as heparin that inhibit activated clotting factors.
Oral anticoagulants and heparins are roughly equally
effective in preventing venous thrombosis. However,
these two families of drugs are essentially different in
their mode of action. They each have numerous proper-
ties in addition to their anticoagulant action, but for
neither of the two has it been demonstrated that it is
indeed the anticoagulant action that is responsible for the
antithrombotic effect. Yet, the anticoagulant action is the
only action that they have in common. Therefore we
consider it more likely than not that the anticoagulant
property bears some direct relationship to the therapeutic
effect. Despite active research on platelet aggregation
inhibitors for over 25 years, it is now generally acknowl-
edged that these substances make less effective an-
tithrombotic agents than anticoagulants do.1 It must even
be considered a possibility that antiplatelet drugs act via
an activation on platelet-induced thrombin formation.'
We will therefore discuss the mode of action of
heparins and other thrombin scavengers in terms of
inhibition of the coagulation process.
Neither oral anticoagulants nor heparins are ideal
drugs. Oral anticoagulant treatment requires laboratory
control and constant expert supervision. Heparin needs
frequent administration by injection and side effects are
common. Both drugs have a relatively narrow therapeutic
window, that is, the gap between the effective dose and
the dose that will cause bleeding, is not very wide. This
explains why at this moment much active research is
spent in finding more efficient antithrombotics.
In this article we will discuss those drugs, such as
heparin, that are known to scavenge active clotting
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factors. Within this group, there are drugs with quite
dissimilar actions. Pentasaccharide, for instance, only
enhances antithrombin III (AT Ill)-mediated Factor Xa
inactivation, whereas hirudin is a specific thrombin
inhibitor. Yet this group of drugs also has many features
in common, so many, indeed, that we may consider them
to belong to one "superfamily" that we will call "scav-
engins" (Table l). As a typical example we will first
discuss the mode of action of heparin. This requires a
short introduction on the reaction mechanism of blood
coagulation.
THE MECHANISM OF THROMBIN
FORMATION
Three fundamental processes govern the generation
of thrombin in platelet-poor plasma: (1) sequential acti-
vation ofproteases, (2) enhancement ofthe efficiency of
a protease by its complexing to a protein cofactor at a
phospholipid surface, and (3) activation of the protein
cofactors by thrombin, the end product. In plateletrich
plasma one more process should be taken into account:
the platelet membrane flip-floP.
The sequence ofprotease activations differs accord-
ing to the way in which coagulation is triggered. When
the reaction is started with excess tissue thromboplastin,
this is done through the extrinsic pathway: Factor VII*
Factor X-Factor IL In the intrinsic pathway the
reactions can be summarized as: Contact Factors*
Factor IX-Factor X*Factor II. In that case the
contact factors are activated by kaolin, ellagic acid, or
other negatively charged "foreign" surfaces. Under
pathophysiologic onditions, the triggering of coagula-
tion by small'amounts of tissue factor is probably
important. In that case the indirect activation of Factor X
via the action of Factor VII on Factor IX has to be taken
into account. This pathway we called the Josso loop:
Factor VII*Factoi Ix*Factor X+Factor II.3'4
Neither activated Factor VII nor Factor [Xa nor
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TABLE 1. Scavengins: Drugs That Act Directly or
Indirectly by lnactivating Clotting Proteases
Abbreviation Cofacar
Unfractionated heparin
Low MW heparin
Pentasaccharide
Pentosan polysulfate
Stichopus Japonicus mucopolysaccharide
Dermatan sulfate
Lactobionic acid
Hirudin
UFH
LMWH
Penta
PS
SJAMP
DS
LBA
Hir
AT III
A T M
A T M
A T m + x { c t r
A T I t r + H C t r
HCt r
HCt r
None
Factor Xa are very efficient enzymes on their own' All
three need to be adsorbed on a procoagulant lipid surface
review).
Factor Va and Factor VIIIa do not occur as such in
review). At the same time, they undergo shape change
and produce PC containing procoagulant microvesicles'
ThiJconstitutes a third positive feedback mechanism by
thrombin.ll
The essential reactions governing thrombin forma-
tion are summarized in Figure 1.
THE THROMBIN GENERATION CURVE
In Figure 2 we show the features of a thrombin
generation curve. The compulsory thrombin-dependent
activation of Factors V and VIII and, as the case may be,
of platelets (processes c and d) requires a,more or less
pronounced lig time. During this lag tirne slow thrombin
generation by an as yet unknown mechanism causes a
imall amouni of thrombin to arise' One can imagine that
minute amounts of thrombin can be formed without the
cofactors present or that occasional molecules of the
cofactors are activated via alternative pathways' Any-
how, the presence of a small amount of thrombin during
a certain iime is necessary for the full activation of the
system and for explosive further thrombin formation'
Of the three feedback mechanisms, that of Factor V
is associated with the smallest lag time, that of Factor
VIII takes more time, and that of platelets still rnore'
Therefore the lag times in the extrinsic system are short,
in the intrinsic system they are longer, and in platelet-rich
plasma they are the longest.
' 
Clotting times are essentially experimental determi-
nations of this lag time, clotting ensuing invariably when
about 20 nM of thrombin has fornred. The classic clotting
tests do not measure the amount of thrombin formed' In
pathophysiologic situations very probably both the lag
I
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FlG. 1. A scheme of blood coagulation Solid arrows indi-
cate sequential activations, dashed arrows show.chemical
conuersions, dotted arrows, feedback activations' PL: phos-
pholipid; TF: tissue factor.
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FlG. 2. The thrombin generation curve, The ordinate is
nonlinear in that the range of 0 to 1 (gray zone) has been
extended in order to visualize the generation of small
amounts of thrombin during the lag phase. a: normal curve;
b: curve in the presence of a scavengin; t: lag time; p: peak
amount; s: surface under the curve.
time and the amount of thrombin formed in situ at the site
of a vessel injury determine the thrombotic or hemostatic
reaction. This may be the reason why there are so often
discrepancies between the prolongation of a clofting time
by a scavengin and its antithrombotic action. Often, no
influence on clotting time tests is interpreted as no
influence on thrombin generation. From this enor to the
conclusion that there exist scavengins that do not influ-
ence blood coagulation is a small, and often encountered,
but illogical step. In fact, every scavengin that we tested
thus far (essentially those mentioned in Table 1) mark-
edly influenced the amount of thrombin formed. That is
why we are developing a test that responds to the area
under the thrombin generation curve rather than to its lag
time.
MODE OF ACTION OF HEPARIN
Heparin influences thrombin generation in two
ways, both of which are due to its enhancing the
thrombin-inactivation rate. There is the effect on the bulk
amount of active thrombin present at any moment and the
effect on the lag time that is caused by the diminution of
the minute amounts of thrombin necessary for feedback
activation. Although both effects are caused by the
scavenging of thrombin, they are not invariably coupled.
Heparin will, for instance, hardly influence the lag time
of the extrinsic system (thromboplastin time), but it will
exert a marked influence of the lag time of the intrinsic
system (activated partial thromboplastin time) and on the
clotting time of platelet-rich plasma. The reason for this
3 1
is that the intricate kinetics of clotting factor activation
are not the result of a simple relationship between the
amount of tkombin present during the lag time and the
formation of prothrombinase (see later).
Heparin has been shown to have, in the extrinsic
system, only an insignificant effect on prothrombinase
(that is, Factor Xa-Va-phospholipid).activity, despite its
definite anti-Factor Xa activity.z'rz''r This may be ex-
plained by the relative excess of Factor Xa in clotting
plasma. The maximal velocity of thromtin generation
that we observed is about 300 nM' min-'. The turnover
number of a complete prothrombinase moiety (Factor
Xa, Factor Va, phospholipid) is on the order of 2000
min-r.l4 This allows us to estimate the maximum
prothrombinase plasma concentration as 0.15 nM. The
plasma concentrations of both Factor V (25 nM) and
Factor X (200 nM) are much higher than this. This means
that only a small fraction of Factor V has to be activated
to stimulate the system. This may explain the short lag
times in the extrinsic system. It also explains why
prothrombinase generation is virtually insensitive to^Factor 
Xa inhibition. Indeed, Pieters et alls showed that
it is possible to inhibit Factor Xa generation so as to have
no measurable Factor Xa present (<0.5 nM) and yet to
obtain full prothrombinase activity, pro-vided that suffi-
cient Factor Va (l nM) was available.t)
In the intrinsic system we cannot for the moment
make an educated guess of the amount of tenase neces-
sary to trigger explosive thrombin formation, but the
qualitative data are clear. The rate-limiting step is the
thrombin-dependent activation of Factor VIII' Heparin
inhibits because it diminishes the thrombin level that
activates Factor VIII during the lag time' In any case the
main action of heparin is via the inhibition of thrombin
and thrombin-rn"diated feedback mechanisms. 2'12'13'16
LOW MOLECULAR WEIGHT HEPARINS
Apart from pentasaccharide and related ultra low
molecular weight heparins (ULMWH), all heparins act
essentially likJ unfrictionated heparin (UFH).2'12 The
low molecular weight heparins (LMWH) that are in
medical use at the moment do not belong to the ULMWH
group. In platelet-poor plasma the action on the biochem-
ical mechanism of thrombin formation is essentially
identical for LMWH and UFH. We therefore group them
together as S heparins (they behave as standard heparin).
The ULMWH group we called P heparin (for penta-
saccharide).2
Even though the anti-Xa action of LMW S heparins
is higher than their anti-Ila action (taking normal heparin
as the reference material),17-22 thisdoes not result in their
inhibiting at the level of protkombinase (where Factor
0
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Xa is the active enzyme) because of the large Factor X
reserve in plasma, as already explained. This is why a
heparin concentration expressed in anti-Xa units does not
give a realistic picture of its anticoagulative power'
Pentasaccharide and other P-type heparins pose a
conceptual problem to some people because they do not
act on thrombin and they still are antithrombotic. This.is
in apparent contradiction with the concept of thrombin
inhibition as being crucial to the antithombotic action. It
should be remembered, however, that any anti-Xa action
eventually results in less thrombin being formed. We
have demonstrated that pentasaccharide acts on free
Factor Xa.22 In this case, where no anti-Ila action is
present, the inhibition of Factor Xa can be so important
ihat it becomes rate limiting. With any heparin that does
have an anti-Ila action, this action always ovemrles the
anti-Xa action. At the moment, we are trying to find,
with the aid of precisely defined heparin fractions, at
what molecular weight the P-S transition takes place.
Obiter dictum: The fact that pentasaccharide does not
influence the anti-Ila action of AT III does pose a
theoretical problem. If pentasaccharide induces a con-
formational change in AT III that makes it more active
toward Factor Xa, it is difficult to conceive why it should
not also have a certain action on the AT Ill-thrombin
interaction. Evidently, the mechanism is more compli-
cated than commonly thought. That the anti-Xa action of
pentasaccharide oes not per se constitute its antithrom-
6otic potency is easily seen from the fact that one needs
to give about 10 times more anti-Xa units of pentasac-
charide compared with UFH to obtain a comparable
antithromboti c effect.23'24
NONHEPARIN SCAVENGINS
The mode of action of the nonheparin scavengins i
again principally the same as that for S heparins:
intriUitibn of thrombin and thrombin-mediated feedback'
This is without doubt the case for hirudin.2s'26 Also, the
heparin cofactor II (HC Il)-dependent scavengins uch as
dermatan sulfate and lactobionic acid act in this way (see
It thus seems that the global mode of action of
scavengins in platelet-poor plasma can be summarized
as: inhibition of thrombin and thrombin-dependent feed-
back reactions noting that for the P heparins this is an
indirect effect mediated by their direct anti-Xa action.
PLATELET.RICH PLASMA
platelets become activated. Once they are activated, they
neutralize the heparin present and thrombin generation
than UFH, maybe because they possess less PF4 binding
sites per molecule or because they contain much' other-
wise inert, PF4 binding material or because they are
100
0
o  s  1 0  1 5
FlG. 3. The influence of heparins on thrombin generation in
platelet-rich plasma. o: control; a : unfractionated heparin
b.t Ul.t (-0.5 rr.g/ml); r : unfractionated heparin 0'2 U/ml( -1.0 pr .g/ml) ;  o :  Frax ipar ine (5 pg/ml) .
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may explain, at least partly, why in pharmacokinetic
studies on LMWH a discrepancy between anti-Xa and
anti-Ila action is often observed.
One may ask why heparin in vivo has an antithrom-
botic action if this action is linked to thrombin inhibition
and if the amount of thrombin is not decreased in
platelet-rich plasma, a situation obviously closer to the in
vivo situation than platelet-poor plasma is. A possible
suggestion for an answer is to be found in the fact that,
in vivo, heparin acts in flowing blood. Due to the flow,
a retardation of thrombin generation will automatically
mean more mixing and dilution and hence lower throm-
bin concentrations, even if the net amount of thrombin
generated is not diminished.
CONCLUSIONS
1. The main mode of action of scavengins is to
decrease the amount of active thrombin and to impair the
thrombin-dependent positive feedback on thrombin gen-
eration.
2. Anti-Factor Xa action is of no importance in
either UFH or LMWH now available to the clinician
(S heparins). In dermatan sulfate and other HC II-
dependent scavengins, it plays no role at all and obvi-
ously not in hirudin either. It comes into play in
pentasaccharide and some other very low molecular
weight heparins (P heparins).
3. A realistic estimate of the potency of a scavengin
can only be made if we take into account its susceptibility
to being neutralized by products from activated platelets.
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